The Effect of Carrier Material on the Measured Resistance of Spores - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Carrier Material on the Measured Resistance of Spores
A biological indicator (BI) measures the effectiveness of the sterilization process to which it is subjected. Factors such as the test organism, the packaging, the culture material, and the test system all influence a BI's resistance. Carrier material is an often-overlooked factor that also influences BI resistance. The authors examine various solid and liquid carriers, describe their properties, and investigate how they influence BI resistance.


Pharmaceutical Technology



Table III: Summary of D-value study results on biological indicators using liquid pharmaceutical products and water for injection (WFI) as the spore carrier.
Commercially available BIs designed to monitor sterilization processes should be correlated to the spore-resistance characteristics of the products that they monitor. This correlation will ensure the most appropriate challenge to the sterilization process. Ideally, the spore carrier of the BI should be composed of materials similar to those processed in the sterilizer. If this situation is not feasible, D-value studies can be performed on component materials in the load to determine the substrate effect of the load. Once the substrate effect is known, an appropriate BI can be selected and correlated to the process.

Kurt McCauley is the research and development laboratory manager and John R. Gillis, PhD,* is the president and CEO of SGM Biotech, 10 Evergreen Dr., Suite E, Bozeman, MT 59715, tel. 406.585.9535, fax 406.585.9219,

*To whom all correspondence should be addressed.

Keywords: biological indicator, carrier material, resistance, spore suspension

References

1. American National Standards Institute, ANSI/AAMI/ISO 14161: Sterilization of Health Care Products—Biological Indicators—Guidance for the Selection, Use, and Interpretation of Results (ANSI, Washington, DC, 2000).

2. V. Sigwarth and A. Stark, "Effect of Carrier Materials on the Resistance of Spores of Bacillus stearothermophilus to Gaseous Hydrogen Peroxide," PDA J. Pharm. Sci. Technol. 57 (1), 3–11 (2003).

3. H. Shintani and J.E. Akers, "On the Cause of Performance Variation of Biological Indicator Used for Sterility Assurance," PDA J. Pharm. Sci. Technol. 54 (4), 332–341 (2000).

4. J.A. Terezina, T. Pinto, and I. Mario, "Ethylene Oxide Sterilization: III—Influence of Carrier Nature in a Biological Monitor Performance," PDA J. Pharm. Sci. Technol. 48 (3), 155–158 (1994).

5. I.J. Pflug, Microbiology and Engineering of Sterilization Processes (Environmental Sterilization Laboratory, Minneapolis, MN, 11th ed., 2003).

6. G.A. Mosley and C.W. Houghtling, "Interpreting and Understanding Microbial Data in Validation of Ethylene Oxide Sterilization Processes," Biomed. Instrum. Technol. 39 (6), 466–482 (2005).

7. S. Hury et al., "A Parametric Study of the Destruction Efficiency of Bacillus Spores in Low Pressure Oxygen-Based Plasmas," Lett. Appl. Microbiol. 26, 417–421 (1998).


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here